The Chinese government said on Tuesday it will scrap long-standing state price controls on most medicines, effective June 1, as part of market-oriented reforms.The government will no longer impose upper limits on retail prices for drugs, government agencies including the National Development and Reform Commission.
“The reform of drug prices needs to… fully utilise the resource allocation role of the market,” the statement said.
Price controls will be relaxed over drugs covered by medical insurance, blood products, immunisations, anti-AIDS and birth-control medicines, the statement said.
“The reform of drug prices needs to… fully utilise the resource allocation role of the market,” the statement said.
Price controls will be relaxed over drugs covered by medical insurance, blood products, immunisations, anti-AIDS and birth-control medicines, the statement said.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Spain’s BBVA Remains Optimistic About Hostile Takeover of Sabadell
Mar 18, 2025 by
CPI
BlackRock, Vanguard and State Street Seek Dismissal of Texas Antitrust Lawsuit
Mar 18, 2025 by
CPI
EU to Boost Metal Sectors with Energy Relief and Safeguards
Mar 18, 2025 by
CPI
Players’ Association Sues Tennis Governing Bodies Over Alleged Antitrust Violations
Mar 18, 2025 by
CPI
Turkey Moves to Curb Big Tech’s Power with New Regulatory Bill
Mar 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Self-Preferencing
Feb 26, 2025 by
CPI
Platform Self-Preferencing: Focusing the Policy Debate
Feb 26, 2025 by
Michael Katz
Weaponized Opacity: Self-Preferencing in Digital Audience Measurement
Feb 26, 2025 by
Thomas Hoppner & Philipp Westerhoff
Self-Preferencing: An Economic Literature-Based Assessment Advocating a Case-By-Case Approach and Compliance Requirements
Feb 26, 2025 by
Patrice Bougette & Frederic Marty
Self-Preferencing in Adjacent Markets
Feb 26, 2025 by
Muxin Li